The raised adjusted EBITDA guidance (+$20M at midpoint) and $50M buyback authorization provide near-term support, but the 30% revenue decline and 90% GAAP net income drop signal structural headwinds in core MCM franchises. Monitor Q2 revenue guidance of $170-185M for sequential improvement and watch for further USG contract awards to validate the turnaround narrative.
Price Chart
Executive Summary
Emergent BioSolutions reported Q1 2026 revenue of $156.1M (above the high-end of guidance) but GAAP EPS of $0.07 missed the consensus estimate of -$0.25 by a wide margin. Revenue fell 30% YoY driven by declines in Anthrax and Smallpox MCM product sales, though the company raised its full-year adjusted EBITDA guidance to $155-175M from $135-155M, signaling improved operational efficiency.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $156.1M, down 30% YoY from $222.2M
- GAAP net income $6.8M ($0.07 diluted EPS) vs $68.0M ($1.19) in Q1 2025
- Adjusted net income $11.9M ($0.21 diluted EPS) vs $42.2M ($0.74) YoY
- Adjusted EBITDA $35.6M (23% margin) vs $79.1M (36% margin) YoY
- Raised FY2026 adjusted EBITDA guidance to $155-175M from $135-155M; revenue guidance unchanged at $720-760M
- Naloxone product sales down 5% YoY to $42.9M; Anthrax MCM down 55% to $21.6M; Smallpox MCM down 40% to $64.2M
- Board authorized $50M share repurchase program through March 2027
- Refinanced term loan with new $150M facility and amended ABL facility
- Secured over $60M in new USG contract awards for smallpox MCM and ~$140M in Canadian government contracts
Financial Impact
Revenue decline of $66.1M YoY (30%); adjusted EBITDA guidance raised by $20M at midpoint
Risk Factors
- Continued decline in Anthrax and Smallpox MCM revenue due to timing of USG purchases and international orders
- Naloxone franchise faces OTC price-volume mix pressure and generic competition
- High debt load ($573.6M) with interest expense of $11M/quarter limits financial flexibility
- Dependence on government contract timing creates lumpy revenue recognition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285513 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | Press Release | $4.45 $5.68 | ▼ −27.64% | ▼ −28.70% | $6.29 (−41.35%) |
Jun 29, 2026 13w ago | 8-K | $8.46 $7.26 | ▼ −14.18% | ▼ −13.90% | $6.29 (−25.65%) |
Jun 4, 2026 17w ago | Press Release | $8.44 $8.28 | ▼ −1.90% | ▼ −0.52% | $6.29 (−25.47%) |
Apr 30, 2026 22w ago | Press Release | $8.47 $8.49 | ▲ +0.24% | ▼ −5.05% | $6.29 (−25.74%) |
Apr 30, 2026 22w ago | Insider Cluster | $8.23 $9.18 | ▲ +11.54% | ▲ +6.58% | $6.29 (−23.57%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 29, 2026 22w ago | Press Release | $7.99 $9.18 | ▲ +14.89% | ▲ +8.85% | $6.29 (−21.28%) |
Apr 28, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 28, 2026 22w ago | Press Release | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
Apr 27, 2026 22w ago | DEFA14A | $8.23 $9.13 | ▲ +10.94% | ▲ +5.47% | $6.29 (−23.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access